Cholecystectomy as a risk factor of non-alcoholic fatty liver disease progression

Cover Page

Cite item

Full Text

Abstract

Association between non-alcoholic fatty liver disease (NAFLD), cholelithiasis, and cholecystectomy is a research subject for biochemists, pathophysiologists, morphologists and clinical physicians. Association between cholelithiasis and NAFLD is mostly presented by insulin resistance. Although in present years solid evidence have emerged showing that not so much cholelithiasis as cholecystectomy has an important role in NAFLD progression. It is determined by endocrine balance and bile acids signal function disturbance as well as by small bowel bacterial overgrowth syndrome development. Further study of these interrelations not only will allow holding from unreasonable surgeries, but will also offer perspectives for development of new treatment methods.

About the authors

Aleksei O. Bueverov

Sechenov First Moscow State Medical University (Sechenov University); Vladimirskiy Moscow Regional Research Clinical Institute; United Medical Systems Group of Companies

Email: bcl72@yandex.ru
D. Sci. (Med.), Prof. Moscow, Russia

References

  1. Adams L.A, Anstee Q.M, Tilg H, Targher G. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-53.
  2. Estes C, Anstee Q.M, Arias-Loste M.T. Modeling NAFLD burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018. pii: S0168-8278(18)32121-32124.
  3. Li A.A, Ahmed A, Kim D et al. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver 2019. doi: 10.5009/gnl19069.
  4. Sayiner M, Koenig A, Henry L, Younossi Z.M. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016; 20: 205-14.
  5. Bellentani S. The epidemiology of nonalcoholic fatty liver disease. Liver Int 2017; 37 (Suppl. 1): 81-4.
  6. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65: 146-81.
  7. Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia NC et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol 2005; 100: 827-30.
  8. Ahmed M.H, Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol 2014; 49: 521-7.
  9. Arrese M, Cortés V, Barrera F, Nervi F. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship. Curr Opin Gastroenterol 2018; 34 (2): 90-6.
  10. Самсонов А.А., Плотникова Е.Ю., Рубан А.П. и др. Желчнокаменная болезнь, холецистэктомия - что дальше? Мед. совет. 2014; 4: 50-4. @@Samsonov A.A., Plotnikova E.Iu., Ruban A.P. et al. Zhelchnokamennaia bolezn', kholetsistektomiia - chto dal'she? Med. sovet. 2014; 4: 50-4 (in Russian)
  11. Cammert F, Gurusamy K, Ko C.W et al. Gallstones. Nat Rev Dis Primers 2016; 2: 16024.
  12. Chiang J.Y. Bile acid metabolism and signaling. Comprehens Physiol 2013; 3: 1191-212.
  13. Jaruvongvanich V, Sanguankeo A, Upala S. Significant association between gallstone disease and nonalcoholic fatty liver disease: a systematic review andmeta-analysis. Dig Dis Sci 2016; 61: 2389-96.
  14. Housset C, Chretien Y, Debray D, Chignard N. Functions of the gallbladder. Comprehens Physiol 2016; 6: 1549-77.
  15. Koller T, Kollerova J, Hlavaty T et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol 2012; 47: 197-203.
  16. Cortes V, Quezada N, Uribe S et al. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in nonobese Hispanic patients: a pilot study. Lipids in health and disease 2017; 16: 129.
  17. Chang Y, Noh Y.H, Suh B.S et al. Bidirectional association between nonalcoholic fatty liver disease and gallstone disease: a cohort study. J Clin Med 2018; 7 (11). pii: E458.
  18. Rosso C, Mezzabotta L, Gaggini M et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology 2016; 63: 107-16.
  19. Li S, Brown M.S, Goldstein J.L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010; 107: 3441-6.
  20. Lambert J.E, Ramos-Roman M.A, Browning J.D, Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146: 726-35.
  21. Tanaka N, Aoyama T, Kimura S, Gonzalez F.J. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther 2017; 179: 142-57.
  22. Arab J.P, Karpen S.J, Dawson P.A et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 2017; 65: 350-62.
  23. Amigo L, Husche C, Zanlungo S et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int 2011; 31: 52-64.
  24. Portincasa P, Di Ciaula A, Wang H.H et al. Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology 2008; 47: 2112-26.
  25. Roda E, Aldini R, Mazzella G et al. Enterohepatic circulation of bile acids after cholecystectomy. Gut 1978; 19: 640-9.
  26. Deutschmann K, Reich M, Klindt C et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim Biophys Acta 2017.
  27. Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.
  28. Kliewer S.A, Mangelsdorf D.J. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis 2015; 33: 327-31.
  29. Barrera F, Azocar L, Molina H et al. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Ann Hepatol 2015; 14: 710-21.
  30. Wojcik M, Janus D, Dolezal-Oltarzewska K et al. A decrease in fasting FGF19 levels is associated with the development of nonalcoholic fatty liver disease in obese adolescents. J Pediat Endocrinol Metab 2012; 25 (11-12): 1089-93.
  31. Pols T.W, Noriega L.G, Nomura M et al. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 2011; 29: 37-44.
  32. Keitel V, Haussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 2012; 36: 412-19.
  33. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-77.
  34. Jones S.A. Physiology of FGF15/19. Adv Exp Med Biol 2012; 728: 171-82.
  35. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2013; 368 (1-2): 17-29.
  36. Cortes V, Quezada N, Uribe S et al. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in nonobese Hispanic patients: a pilot study. Lipids in health and disease 2017; 16: 129.
  37. Лебедева О.В., Буеверов А.О., Буеверова Е.Л., Никитина Л.О. Влияние холецистэктомии в молодом возрасте на течение метаболического синдрома у женщин. Альманах клин. мед. 2017; 45 (6): 326-33. @@Lebedeva O.V., Bueverov A.O., Bueverova E.L., Nikitina L.O. Vliianie kholetsistektomii v molodom vozraste na techenie metabolicheskogo sindroma u zhenshchin. Al'manakh klin. med. 2017; 45 (6): 326-33 (in Russian).]
  38. Ruhl C.E, Everhart J.E. Relationship of nonalcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol 2013; 108: 952-8.
  39. Ioannou G.N. Cholelithiasis, cholecystectomy, and liver disease. Am J Gastroenterol 2010; 105: 1364-73.
  40. Kwak M.S, Kim D, Chung G.E et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol 2015; 21: 6287-95.
  41. Yun S, Choi D, Lee K.G et al. Cholecystectomy causes ultrasound evidence of increased hepatic steatosis. World J Surg 2016; 40: 1412-21.
  42. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol 2013; 108: 959-61.
  43. Shen C, Wu X, Xu C et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PloS One 2014; 9: e88189.
  44. Hajong R, Dhal M.R, Naku N et al. Incidence of nonalcoholic fatty liver disease in patients undergoing laparoscopic cholecystectomy. J Family Med Prim Care 2018; 7 (6): 1375-8.
  45. Khaw K.B.C, Choi R.H, Kam J.H et al. Interval increase in the prevalence of symptomatic cholelithiasis-associated non-alcoholic fatty liver disease over a ten-year period in an Asian population. Singapore Med J 2017; 58 (12): 703-7.
  46. Guo L, Mao J, Li Y et al. Cholelithiasis, cholecystectomy and risk of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 2014; 10 (4): 834-8.
  47. Chen Y, Wu S, Tian Y et al. Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. Lab Invest 2018; 98 (1): 7-14.
  48. Ratziu V, de Ledinghen V, Oberti F et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54 (5): 1011-9.
  49. Leuschner U.F, Lindenthal B, Herrmann G et al. NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52 (2): 472-9.
  50. Xiang Z, Chen Y.P, Ma K.F et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13: 140.
  51. Stokes C.S, Gluud L.L, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2014; 12 (7): 1090-100

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies